(PCLN) Booking.com’s Mobile Bookings Grow 160% in 2013

(QLTY) Expands Into Denver Market

TAMPA, Fla., Feb. 21, 2014  — Quality Distribution, Inc. (Nasdaq:QLTY) (“Quality”) announces its wholly-owned subsidiary, Quality Carriers, Inc. (“Quality Carriers”), the leading North American bulk chemical carrier, has expanded into the Denver, Colorado market.

“As the leading bulk carrier in North America, we’ve listened to our customers who have asked for options in the Denver market, both for local shipments as well as long haul,” commented Randy Strutz, President, Quality Carriers.  “We’ve partnered with Kemps Transport, an experienced food grade carrier, to expand into the chemical segment.”

“As a food grade carrier, I wanted to diversify into chemicals and Quality Carriers enabled this through their affiliate program,” stated Robert Kemp, President, Kemps Transport.

“We continue to review other under served markets and expect to aggressively expand our footprint to serve our customers and increase our driver capacity,” continued Randy Strutz.

Headquartered in Tampa, Florida, Quality Carriers operates the largest chemical bulk logistics network in North America. Quality Carrier’s network of independent affiliates and independent owner-operators provides nationwide bulk transportation and related services. Quality Carriers is an American Chemistry Council Responsible Care® Partner and is a core carrier for many of the Fortune 500 companies that are engaged in chemical production and processing.

CONTACT: Christine Craig
         CFO, Quality Carriers
         800-282-2031 ext. 7386

(ARWR) Listing Upgraded to NASDAQ Global Select Market

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received notice that the NASDAQ Listing Qualifications Department has approved an application to upgrade the listing of the Company’s securities from the NASDAQ Capital Market to the NASDAQ Global Select Market, effective with the opening of business on February 21, 2014. The NASDAQ Global Select Market is the segment for public companies that meet the highest listing standards of NASDAQ, with requirements that include market value, financial, and liquidity measurements. The Company’s stock will continue to trade under the ticker symbol “ARWR” after the upgrade.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology.

For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company’s email list to receive news directly, please send an email to ir@arrowres.com.

(IMMR) to Demonstrate Tactile Video and Wearables Experiences at Mobile World Congress 2014

Immersion Corporation (Nasdaq:IMMR), the leading developer and licensor of touch feedback technology, will be unveiling new demonstrations at Mobile World Congress designed to show how tactile technology will enhance user experience in next-generation mobile and wearable devices. The demos highlight applications of haptics in user-created video, tactile ads and entertainment, wearables, mobile user interfaces and gaming. The company will showcase its technology at GSMA Mobile World Congress 2014, February 24 – 27 in Barcelona. Immersion will be located at App Planet Hall, Stand 8.1G41.

“Mobile World Congress is a great opportunity for us to pull back the curtain and share new technologies we’re investing in to offer haptics more broadly to the mobile ecosystem, including OEMs, advertisers, developers, content owners and publishers,” explains Dennis Sheehan, senior vice president of sales and marketing at Immersion. “Our experiential demonstrations use technologies that will reach consumers over the next 1-3 years; we’re offering visitors an opportunity to experience how haptics will transform mobile video, ads, entertainment and communications into immersive, multi-sensory experiences.”

Tactile Effects in User-Created Video

Tactile effects offer consumers a new way to customize and enhance mobile videos. With tactile effects, users can engage the sense of touch to exaggerate, emphasize and intensify physical feats, incorporate personal commentary and express emotions in personal videos. Imagine a user adding a haptic heartbeat to a video of a new puppy, or the realistic sensation of rolling up a ramp to a skateboard video. With new Immersion technology, tactile effects can be added into user captured video and shared with others, who can then feel the experience on their own device.

In addition to on-device editing demonstrations, Mobile World Congress visitors will be able to preview Immersion’s research and development efforts in sensor-based tactile technology. With sensor-based haptics, data captured from gyros and accelerometers affixed to athletes are translated into haptic tracks, which are then embedded into mobile video. The unprecedented sense of realism offered by haptics captured by sensor data allows viewers to feel the pavement underneath a skateboarder, the rev of the engine in motocross or the impact of a crash from a BMX rider.

Tactile Ads and Entertainment

User research has shown that incorporating tactile effects into mobile ads and entertainment results in increased key performance indicators, including brand perception, intent to purchase and user engagement. Additionally, tactile ads and entertainment have been shown to increase long-term recall of content, while providing an opportunity for advertisers and content owners to direct attention and alter media experience. At Mobile World Congress, Immersion will be demonstrate the latest examples of tactile ads and entertainment, and will preview tools the company is developing for advertisers, publishers and agencies to incorporate tactile effects into mobile content.

Wearables

Tactile feedback provides personal, private and discreet communication between a wearable device and its user. By using Immersion technology, OEMs can create a unique language of communication, based on distinct tactile effects, to provide rich meaningful information to users. Demonstrations will let visitors feel a wide range of use cases for tactile communications in wearables including rich alerts and notifications, smart home controls, health and fitness applications, and gaming.

Mobile UX and Gaming

Immersion’s tactile technology provides OEMs and game developers the opportunity to create a user experience that is branded and distinct, as well as more intuitive. Seemingly simple tactile enhancements go a long way to reduce user frustration and create a rich, delightful mobile user experience. From chat and messaging applications to camera and video capture, text entry, utilities, and connectivity, Immersion will be demonstrating novel ways that tactile effects can enhance mobile UX. Also on display will be third-party applications using Immersion’s Haptic SDK for Android game developers. The Haptic SDK offers tools and effect libraries that make it easy to incorporate tactile effects into Android games. To date, it has been used to enhance thousands of Android games which, on aggregate, have been downloaded over 80 million times.

About Immersion (www.immersion.com)

Founded in 1993, Immersion (NASDAQ: IMMR) is the leading innovator in haptic technology; the company’s touch feedback solutions deliver a more compelling sense of the digital world. Using Immersion’s high-fidelity haptic systems, partners can transform user experiences with unique and customizable touch feedback effects; excite the senses in games, videos and music; restore “mechanical” feel by providing intuitive and unmistakable confirmation; improve safety by overcoming distractions while driving or performing a medical procedure; and expand usability when audio and visual feedback are ineffective. Immersion’s TouchSense technology provides haptics in mobile phone, automotive, gaming, medical and consumer electronics products from world-class companies. With over 1,400 issued or pending patents in the U.S. and other countries, Immersion helps bring the digital universe to life. Hear what we have to say at blog.immersion.com.

Forward-looking Statements

This press release contains “forward-looking statements” that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause the results of Immersion Corporation and its consolidated subsidiaries to differ materially from those expressed or implied by such forward-looking statements.

All statements, other than the statements of historical fact, are statements that may be deemed forward-looking statements, including, but not limited to, statements regarding the benefits of Immersion’s demonstrations, that the demonstrations will perform as intended, Immersion’s anticipation that the technologies embodied in the demonstrations will reach consumers in the future, and that Immersion will make available tools currently under development or continue their development.

Immersion’s actual results might differ materially from those stated or implied by such forward-looking statements due to risks and uncertainties associated with Immersion’s business, which include, but are not limited to: unanticipated difficulties and challenges encountered in product development efforts by Immersion and its licensees; unanticipated difficulties and challenges encountered in implementation efforts by Immersion’s licensees; adverse outcomes in any future intellectual property-related litigation and the costs related thereto; the effects of the current macroeconomic climate; delay in or failure to achieve commercial demand for Immersion’s products or third party products incorporating Immersion’s technologies; and a delay in or failure to achieve the acceptance of touch feedback as a critical user experience. Many of these risks and uncertainties are beyond the control of Immersion.

For a more detailed discussion of these factors, and other factors that could cause actual results to vary materially, interested parties should review the risk factors listed in Immersion’s most current Form 10-Q, which is on file with the U.S. Securities and Exchange Commission. The forward-looking statements in this press release reflect Immersion’s beliefs and predictions as of the date of this release. Immersion disclaims any obligation to update these forward-looking statements as a result of financial, business, or any other developments occurring after the date of this release.

The use of the word “partners” in this press release does not mean legal partners.

Immersion, the Immersion logo, and TouchSense are trademarks of Immersion Corporation in the United States and other countries. All other trademarks are the property of their respective owners.

(RSYS) Collaborates with VMware to Deliver Virtualized Media Processing for the Telecom Cloud

Radisys^® Corporation:

News Highlights:

• Radisys’ Software MRF implementation of VMware vSphere® 5.5 delivers virtualized high-performance media processing with minimized delay for real-time communications services
• Supports VMware vSphere vMotion, allowing live migration of running Software MRF virtual machines from one physical server to another with minimal downtime, continuous availability and complete transaction integrity
• Delivers more than 90 percent capacity compared to Software MRF running on a bare metal server
• European mobile operator lined up to begin VoLTE services trial using virtualized media processing based on latest offerings from Radisys and VMware

Radisys^® Corporation (NASDAQ: RSYS), a market leader enabling wireless infrastructure solutions, today announced the integration of VMware vSphere® 5.5, the industry’s leading virtualization platform, with Radisys’ Software MRF to deliver virtualized media processing capabilities for mobile operators’ telecom cloud deployments.

Mobile operators are turning to the cloud to realize economies of scale, cost effectiveness, scalability and lower CapEx and OpEx. These telecom cloud implementations require the flexibility and economics of using virtual machines, and a hypervisor layer allows multiple virtual machines to run on a single server. However, a hypervisor can also introduce timing issues that can affect the real-time performance that is essential for telecommunications services. Radisys’ Software MRF integrated with VMware’s vSphere 5.5 is engineered to ensure optimized media processing performance in virtualized environments, even under high system load, with more than 90 percent of the capacity as compared to the Software MRF running on a bare metal server.

“We are pleased to work with Radisys and to see Radisys’ Software MRF taking full advantage of the low latency features of vSphere® 5.5,” said Sanjay Katyal, vice president, Global Strategic Alliances, VMware. “With this collaboration, we’re enabling mobile operators around the world to realize the promise of the telecom cloud.”

Radisys’ MRF Release 1.7 also works with VMware vSphere vMotion® to enable the live migration of Radisys’ MRF virtual machines from one physical server to another, providing mobile operators with the flexibility to balance their virtual machines across their servers with minimal downtime, continuous availability and complete transaction integrity.

“Bringing together the combined engineering expertise of Radisys’ media processing experts with VMware vSphere 5.5 has enabled us to deliver an MRF solution that ensures the real-time processing performance of media packet streams in a virtualized environment with impeccable audio and video media quality,” said Denis Bouffard, director of product management, Radisys. “We designed our Software MRF Release 1.7 to embrace all of the real-time application improvements in VMware vSphere 5.5 to deliver a powerful virtualized MRF solution to the market, and we have several mobile operators lined up to start pilot deployments.”

See Radisys’ Media Processing Solutions at Mobile World Congress

Radisys will be showcasing its MRF solutions at Mobile World Congress in Hall 5, Stand 5I61, February 24-27 in Barcelona. To schedule a meeting with Radisys, contact info@radisys.com.

About Radisys

Radisys (NASDAQ: RSYS) is a market leader enabling wireless infrastructure solutions for telecom, aerospace and defense applications. Radisys’ market-leading MRF (Media Resource Function) and T-Series Virtualized Platforms coupled with Trillium software, services and market expertise enable customers to bring their products to market faster with lower investment and risk. Radisys technology is used in a wide variety of 3G & 4G / LTE mobile network applications including: small cell Radio Access Networks (RAN), wireless core network elements, deep packet inspection (DPI) and policy management equipment; conferencing and media services including voice, video and data, as well as commercial offerings for network applications that support the aerospace and defense markets.

Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.

VMware, vSphere and vMotion are registered trademarks or trademarks of VMware, Inc. in the United States and other jurisdictions.

(ISIS) ISIS-SMN Rx Multiple Dose Study In Children with Spinal Muscular Atrophy

Average increase of 3.7 points observed in muscle function score in SMA children treated with 9 mg of ISIS-SMN Rx ISIS-SMN Rx increases SMN protein in children with SMA On track to initiate Phase 3 study in children with SMA later this year Conference Call Scheduled for February 24, 2014 at 8:30 am Eastern Time

CARLSBAD, Calif., Feb. 21, 2014 /PRNewswire/ — Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced top-line results from an ongoing open-label, multiple-dose study of ISIS-SMN_Rx in children with spinal muscular atrophy (SMA). In this study, ISIS-SMN_Rx was well tolerated at all dose levels in children with SMA.  Consistent with single-dose observations, time- and dose-dependent increases in muscle function were observed in children treated with multiple doses of ISIS-SMN_Rx. In addition, results from a recently developed biomarker assay that was designed to measure levels of SMN protein in the cerebral spinal fluid (CSF), showed time- and dose-dependent increases in SMN protein levels in SMA children treated with ISIS-SMN_Rx from both single- and multiple-dose studies.

“We continue to be encouraged with the tolerability of ISIS-SMN_Rx we have observed in our clinical studies to date. We are also encouraged that we observed dose- and time-dependent increases in muscle function scores in children with SMA. The consistency of the results between the single-dose and the multiple-dose studies supports our earlier optimism around the single dose study results and gives us further confidence to advance ISIS-SMN_Rx into a Phase 3 program in children with SMA, which we plan to start later this year,” said B. Lynne Parshall, chief operating officer.

In the interim analysis of this ongoing multiple-dose Phase 1b/2a study, children with Type II or Type III SMA were dosed intrathecally with 3 mg, 6 mg or 9 mg of ISIS-SMN_Rx.  The 3 mg and 6 mg doses were administered on days 1, 29 and 85.  The 9 mg dose was administered on days 1 and 85.  Muscle function changes were measured using the Hammersmith Functional Motor Scale-Expanded (HFMSE), a validated method to measure changes in muscle function in patients with SMA.  Using this test, dose-dependent increases in muscle function scores were observed in this study.  SMA children in the 3 mg, 6 mg and 9 mg cohorts achieved mean increases in HFMSE scores of 1.5, 2.3 and 3.7 points, respectively, nine months following the first dose of ISIS-SMN_Rx.  In addition, time-dependent increases in muscle function scores were observed.  Children in the 9 mg cohort achieved mean increases in HFMSE scores of 2.7 and 3.7 points three and nine months after the first dose of ISIS-SMN_Rx, respectively.  The increases in muscle function scores observed in this study at the three month time point is comparable to the single-dose data presented last year, which showed that children treated with 9 mg of ISIS-SMN_Rx achieved a mean increase in HFMSE score of 3.1 three months after the single-dose.  All children in the multiple-dose study have completed dosing in the initial three cohorts and the first child has been dosed in the 12 mg cohort.  Isis’ plans to give all children who roll over into an extension study a maintenance dose of 12 mg of ISIS-SMN_Rx every six months.  To date, ISIS-SMN_Rx has been well tolerated.  Two serious adverse events (pneumonia and fentanyl-related hypersensitivity) that were not considered drug related were reported.

“A subgroup analysis that combines data from children in both the single- and multiple-dose studies demonstrated a mean 5 point increase in muscle function score in children who received at least 9 mg of ISIS-SMN_Rx between the ages of two and 10 who did not have severe scoliosis or baseline HFMSE scores at the extreme low or high ends of the scale. These results provide us with valuable insight into determining which children with SMA can achieve increases in Hammersmith scores that best correlate with increases in muscle function,” said C. Frank Bennett, Ph.D., senior vice president of research.  “Because we saw increases in muscle function scores up to 14 months after treatment in our single-dose study, we will continue to monitor the patients from our multiple dose study who enter the extension study for longer-term changes in muscle function scores.  Given the long half-life of ISIS-SMN_Rx and the complexity of a process that starts with increasing SMN protein production and ends with improvements in muscle function, it makes sense that the effects of ISIS-SMN_Rx are both dose and time dependent.”

In addition, analysis of CSF samples from both the single dose and the ongoing multiple dose studies demonstrated dose-dependent increases in SMN protein levels over time in patients treated with ISIS-SMN_Rx. In the single dose study, SMN protein levels more than doubled in the two highest dose cohorts with average increases of approximately 120% and 160% compared to baseline observed approximately 9-14 months after dosing in the 6 mg and 9 mg cohorts, respectively. Similarly, in the multiple dose study, patients in the 9 mg cohort all exhibited a substantial increase in SMN protein levels. At Day 86, SMN protein levels more than doubled with an average increase of 115% compared to baseline.

Isis plans to report additional detail from this study at an upcoming medical conference.  For further study information, please visit www.clinicaltrials.gov and search for ISIS-SMN_Rx or by the identifier number, NCT01703988.

Conference Call
At 8:30 a.m. Eastern Time Monday, February 24, 2014, Isis will conduct a live conference call to discuss the top-line multiple-dose results. Interested parties may listen to the call by dialing 866-652-5200, or access the audio webcast at www.isispharm.com. A webcast replay will be available for a limited time at the same address.

ISIS-SMN_Rx is also being evaluated in an open-label, multiple-dose, dose-escalation Phase 2 study in infants with Type I SMA. In the ongoing Phase 2 study, doses of either 6 mg or 12 mg are administered intrathecally on Days 1, 15 and 85. All infants from the 6 mg dose cohort have completed the three initially scheduled doses and, under the amended protocol, are eligible to receive an additional 12 mg dose six months after their initial three scheduled doses. Isis announced late in 2013 that the study was expanded to enroll up to 20 infants and that the first infant was dosed in the 12 mg dose cohort. Infants from the 12 mg dose cohort will also be eligible to receive an additional 12 mg dose six months after they have completed the initial three scheduled doses. Infants may enroll in the Phase 2 study if they are between the ages of three weeks and seven months, live in close proximity to a study site and pass screening evaluations conducted at study sites. The study is being conducted at centers in the United States and Canada. For further study information, please visit www.clinicaltrials.gov and search for ISIS-SMN_Rx or by the identifier number, NCT01839656.

ABOUT ISIS-SMN_Rx
ISIS-SMN_Rx is designed to alter the splicing of a closely related gene (SMN2) to increase production of fully functional SMN protein. The United States Food and Drug Administration granted orphan drug status and fast track designation to ISIS-SMN_Rx for the treatment of patients with SMA. Isis is currently in collaboration with Biogen Idec to develop and potentially commercialize the investigational compound, ISIS-SMN_Rx, to treat all types of SMA. Under the terms of the January 2012 agreement, Isis is responsible for global development and Biogen Idec has the option to license the compound until completion of the first successful Phase 2/3 study or the completion of two Phase 2/3 studies.

Isis acknowledges support from the following organizations for ISIS-SMN_Rx: Muscular Dystrophy Association, SMA Foundation, Families of SMA and intellectual property licensed from Cold Spring Harbor Laboratory and the University of Massachusetts Medical School.

ABOUT SMA
SMA is a severe genetic disease that affects approximately 30,000-35,000 patients in the United States, Europe and Japan. SMA is caused by a loss of, or defect in, the survival motor neuron 1 (SMN1) gene leading to a decrease in the survival motor neuron (SMN) protein. SMN is critical to the health and survival of nerve cells in the spinal cord responsible for neuromuscular growth and function. One in 50 people, the equivalent of about 6 million people in the United States, are carriers of a defective SMN1 gene, which is unable to produce fully functional SMN protein. Carriers experience no symptoms and do not develop the disease. However, when both parents are carriers, there is a one in four chance that their child will have SMA. The severity of SMA correlates with the amount of SMN protein. Infants with Type I SMA, the most severe form of the disease, produce very little SMN protein and have a life expectancy of less than two years. Children with Type II have greater amounts of SMN protein but still have a shortened lifespan and are never able to stand independently. Children with Type III have a normal lifespan but accumulate life-long physical disabilities as they grow.

ABOUT ISIS and BIOGEN IDEC
Biogen Idec and Isis have established four collaborations focused on leveraging antisense technology to advance the treatment of neurological and neuromuscular disorders. This alliance combines Isis’s expertise in antisense technology to evaluate potential neurological targets and discover antisense drugs with Biogen Idec’s capability to develop therapies for neurological disorders. Isis is primarily responsible for drug discovery and early development of antisense therapies. Biogen Idec has the option to license each antisense program at a particular stage in development. Current development-stage programs include antisense drugs to treat SMA, ISIS-SMN_Rx, and myotonic dystrophy type 1, ISIS-DMPK_Rx.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis’ broad pipeline consists of 31 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders and cancer. Isis’ partner, Genzyme, is commercializing Isis’ lead product, KYNAMRO®, in the United States for the treatment of patients with HoFH. Isis’ patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS’ FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Isis’ alliance with Biogen Idec, the discovery, development, activity, therapeutic potential, safety and commercialization of ISIS-SMN_Rx and the discovery, development and therapeutic potential of an antisense drug for the treatment of spinal muscular atrophy.  Any statement describing Isis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis’ programs are described in additional detail in Isis’ annual report on Form 10-K for the year ended December 31, 2012, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, “Isis,” “Company,” “we,” “our,” and “us” refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO® is a registered trademark of Genzyme Corporation.

(STML) to Present at Citi 2014 Global Healthcare and RBC Capital Markets Conferences

NEW YORK, Feb. 20, 2014  — Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that it will present at the Citi 2014 Global Healthcare and RBC Capital Markets Global Healthcare conferences in February.

Ivan Bergstein, M.D., Stemline’s CEO, will host investor meetings at the Citi 2014 Global Healthcare Conference on Monday, February 24, 2014. The conference will be held at the Hilton New York Hotel in New York City.

Dr. Bergstein will also present at the RBC Capital Markets Global Healthcare Conference on Wednesday, February 26, 2014 at 4:05 PM ET. The conference will be held at the New York Palace Hotel in New York City. A live webcast of the presentation can be viewed on the Stemline website at www.stemline.com.

About Stemline Therapeutics

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Stemline’s clinical candidates, SL-401 and SL-701, have demonstrated clinical activity, including durable complete responses (CRs), in Phase 1/2 studies of patients with advanced hematologic and brain cancer, respectively. SL-401 is being advanced into later stage programs in blastic plasmacytoid dendritic cell neoplasm (BPDCN) and other rare malignancies, as well as additional hematologic cancers including acute myeloid leukemia (AML) and myeloma. SL-701 is being advanced into later stage trials of adults with second-line glioblastoma multiforme (GBM) and children with brainstem and non-brainstem glioma. For more information about Stemline Therapeutics, visit www.stemline.com.

Forward-Looking Statements

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially are identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

CONTACT: Mark Jacobson
         Director, Corporate Development
         Stemline Therapeutics, Inc.
         750 Lexington Avenue
         Eleventh Floor
         New York, NY 10022
         Tel: 646-502-2307
         Email: mjacobson@stemline.com

(ICLR) Announces Appointment of Ms. Mary Pendergast to Board of Directors

ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Ms. Mary Pendergast, J.D., LL.M., as a non-executive director.

Ms. Pendergast is an expert in the regulatory aspects of drug development and is President of Pendergast Consulting, a consulting firm that advises biopharmaceutical companies, patient groups, professional and advocacy organisations, governments and academic and financial institutions. Prior to founding her own firm, Ms. Pendergast was Executive Vice President of Government Affairs at Elan Corporation from 1998 to 2003. Ms. Pendergast also spent more than 18 years at the US Food and Drug Administration (FDA), serving as Deputy Commissioner and Senior Advisor to the FDA Commissioner and Associate Chief Counsel for Enforcement.

Ms. Pendergast is also a board member of AesRx, ARCH Foundation and Impax Laboratories, Inc.

“We are delighted to welcome Ms. Pendergast to the ICON Board,” commented Chairman, Mr. Thomas Lynch. “Her deep knowledge and understanding of the regulatory environment within the biopharma and medical device industries will be a great asset to the Board and will complement the expertise of our existing Board members.”

This press release contains forward-looking statements. These statements are based on management’s current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word “expected” and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC’s website at http://www.sec.gov.

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development – from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 77 locations in 38 countries and has approximately 10,300 employees. Further information is available at www.iconplc.com.

(SPEX) USPTO Allowance on Rockstar Data Network Patent Application

TYSONS CORNER, Va., Feb. 20, 2014  — Spherix Incorporated (NASDAQ:SPEX) — an intellectual property development company committed to the fostering and monetization of intellectual property, today announced that a “Notice of Allowance and Fees Due” was issued by the USPTO for an important new data network patent. Spherix acquired the patent application from Rockstar Consortium, which holds a multitude of patents obtained from the bankruptcy of Nortel and is owned by Apple, Microsoft, Sony, Ericsson and Blackberry.

(MEET) to Present at the JMP Securities Technology Conference on March 4, 2014

MeetMe, Inc. (NYSE MKT: MEET), the public market leader for social discovery, today announced that the Company will be presenting at the JMP Securities Technology Conference, being held at the Ritz-Carlton in San Francisco, CA on March 3-4, 2014. The Company will be giving its presentation on Tuesday, March 4, 2014 at 2:30 PM Pacific Time.

The presentation by CEO Geoff Cook and CFO David Clark will be webcasted during the event [http://wsw.com/webcast/jmp23/MEET] and will be available on the Investor Relations section of the company’s website, www.meetmecorp.com.

About MeetMe, Inc.

MeetMe® is the leading social network for meeting new people in the US and the public market leader for social discovery (NYSE MKT: MEET). MeetMe makes meeting new people fun through social games and apps, monetized by both advertising and virtual currency. With 60 percent of traffic coming from mobile, MeetMe is fast becoming the social gathering place for the mobile generation. The company operates MeetMe.com and MeetMe apps on iPhone, iPad, and Android in multiple languages including English, Spanish, Portuguese, French, Italian, German, Chinese (Traditional and Simplified), Russian, Japanese, Dutch, Turkish and Korean.

(RPTP) Announces Clinical Results With RP103 in Huntington’s Disease Phase 2/3 Trial

18 Month Clinical Results Showed Significantly Slower Progression of Total Motor Score in RP103 Treated Patients Without Tetrabenazine

Conference Call and Webcast Today at 8:30 a.m. EST

NOVATO, Calif., Feb. 20, 2014  — Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced top line results from a planned 18 month analysis of an ongoing 3 year Phase 2/3 clinical trial of RP103 (delayed-release cysteamine) for the potential treatment of Huntington’s disease (HD) in collaboration with the Centre Hospitalier Universitaire d’Angers (CHU d’Angers). A total of 96 patients with HD were randomized to treatment with RP103 or placebo. Eighty nine patients completed the initial 18 month phase. Analysis of all 96 patients enrolled in the trial showed a positive trend towards slower progression of Total Motor Score (TMS) in patients treated with RP103 vs. those patients on placebo, the primary endpoint of the study. TMS progression was 32% slower in patients treated with RP103 vs. those treated with placebo after 18 months treatment (4.51 vs. 6.68 respectively, p=0.19). In 66 patients not taking concurrent tetrabenazine, RP103 treatment resulted in a statistically significant slower progression in TMS vs. the placebo group (2.84 points vs. 6.78 respectively, p=0.03).

Due to the 36 month duration of the study, patients were allowed to continue their baseline medication regime, including antidepressants and tetrabenazine, the latter being an approved medication to treat chorea associated with HD. Patients were not randomized in the study based on concomitant medications. To confirm that the TMS results were not influenced by a potential treatment effect of tetrabenazine on chorea (a sub-score of TMS) the subset of patients not receiving tetrabenazine were analyzed for TMS. In these 66 patients (32 under placebo and 34 under RP103), RP103 treatment caused a statistically significant 58% slower progression in TMS of 2.84 points compared to 6.78 points for placebo (p=0.03) at 18 months. Slower progression was seen across all TMS sub-score measurements including eye and hand movements, balance and gait, as well as maximal dystonia and maximal chorea. Adverse events were similar in the two groups and were comparable to what has been observed in other studies in this patient population.

“We are very encouraged by these trial results and we believe that the significant slowdown of loss of muscle control in these early stage patients indicates that RP103 is potentially effective at slowing the progression of Huntington’s disease,” said Dr. Christophe Verny, Lead Investigator for the Phase 2/3 clinical trial and Chief of Neurology Department at CHU d’Angers. “We look forward to working with Raptor to develop and implement a continuing access program so that we can continue to provide RP103 to the patients who participated in the study initiated by CHU d’Angers, and avoid any treatment interruption after they finish the study.”

“We are very grateful to the patients who participated in the study and the French clinical network of physicians, led by Drs. Christophe Verny and Dominique Bonneau in Angers,” said Patrice Rioux, M.D., Ph.D., Chief Medical Officer at Raptor. “We are thrilled to build on these results and will engage regulatory agencies to discuss the most efficient means to advance this program to potential approval. These results not only support the safety and efficacy of Raptor’s RP103 in Huntington’s disease, but also the rationale for testing the use of RP103 in other indications such as NAFLD, Leigh Syndrome and mitochondrial diseases.”

RP103 was well tolerated with 48/52 patients experiencing at least one adverse event (AE) during the 18 month study vs. 38/44 under placebo. There were slightly more patients under RP103 than under placebo reporting at least one gastrointestinal AE (61.5% RP103 vs. 45.5% placebo), mostly nausea, vomiting, abdominal pain, constipation and breath odor. There were also slightly more headache AEs on RP103 than on placebo. There were 5 patients treated with RP103 who experienced serious adverse events (SAEs) compared with 4 patients treated with placebo.

Clinical Study Design

The study enrolled 96 patients who were randomized in a double blind, 1:1 ratio to RP103 or placebo for an initial 18 month treatment period followed by 18 months open label treatment with RP103. Concomitant medications were not taken into account in the randomization. Eighty nine patients completed the first 18 month phase. The study enrolled primarily Stage 1/2 patients showing early disease symptoms with a Unified Huntington Disease Rating Scale (UHDRS), Total Motor Score (TMS) ≥ 5, Total Functional Capacity > 10 and a CAG repeat > 38. The trial was conducted at eight clinical sites throughout France under a collaboration agreement between Raptor and CHU d’Angers. Clinical expenses of the study are covered by a grant from the French government (PHRC 2004-03bis CYST-HD).

The objective of the study is to evaluate the effectiveness, safety and tolerability of RP103 in modifying Huntington’s disease progression. The primary endpoint of the study is the change from baseline in the TMS sub-scale of the UHDRS at 18 months of treatment in the placebo and RP103 treated groups. The study was powered to detect a difference in TMS in as few as 62 patients at 18 months. Due to the duration of the study, patients were permitted to continue taking their normal medication regime which included tetrabenazine, a vesicular monoamine transporter 2 inhibitor.

Seven patients discontinued treatment during the study, 6 in the RP103 arm and 1 in placebo. Three patients receiving RP103 discontinued for SAEs including 1 for lymphopenia, 1 for repetitive faintness and 1 for elevated liver enzymes. One SAE in the placebo group, anxiety, resulted in discontinuation.

Conference Call and Webcast

Raptor has scheduled an investor conference call and webcast regarding this announcement at 8:30 a.m. EST (5:30 a.m. PST), February 20, 2014. The live call may be accessed by dialing (877) 870-4263 for domestic callers or (412) 317-0790 for international callers. A live webcast of the conference call will be available online from the investor relations section of the company website at www.raptorpharma.com.  After the call, a webcast replay will be available on the Raptor website for 90 days. A telephone replay of the call will be available by dialing (877) 344-7529 for domestic callers, or (412) 317-0088 for international callers, and entering the conference number: 10041359.

About Huntington’s Disease

Huntington’s disease is a rare, progressive, and hereditary neurological disease that often leads to death within 15 to 20 years after diagnosis. The disease is thought to affect as many as 18,000-30,000 patients in the U.S. and a comparable number in Europe. There are currently no disease modifying therapies approved for Huntington’s disease. HD causes neuronal degeneration in the cerebral cortex and basal ganglia, which play a key role in movement and behavior control. The cumulative damage to these areas results in the hallmark symptoms of chorea (uncontrollable, jerky movements), neuropsychiatric symptoms, loss of executive functioning and dementia.

About Raptor Pharmaceutical

Raptor Pharmaceutical Corp. is a global biopharmaceutical company focused on the development and commercialization of life-altering therapeutics that treat rare, debilitating and often fatal diseases. The company is engaged in multiple therapeutic areas such as nephropathic cystinosis, Huntington’s disease, nonalcoholic fatty liver disease, Leigh syndrome and other mitochondrial diseases.  With an approved product in the U.S. and EU, Raptor also holds several orphan drug designations, including U.S. orphan drug designation for RP103 in Huntington’s disease.  A request for EU designation for RP103 in HD will be submitted with clinical data. Raptor holds intellectual property for the use of cysteamine in HD and other neurodegenerative disorders including Parkinson’s disease, Rett Syndrome and the treatment of MeCP2-associated disorders. For additional information, please visit www.raptorpharma.com.

FORWARD-LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are indicated by words or phrases such as “believes,” “expects,” “anticipates,” “estimates,” “plans,” “continuing,” “ongoing,” “projected” and similar words or phrases and relate to future events or our future results of operations or future financial performance, including, but not limited to, quotes from the lead investigator for the Phase 2/3 clinical trial and management, and statements regarding the potential effectiveness of RP103 at slowing the progression of HD, development and implementation of an early access program, engagement of regulatory agencies and testing the use of RP103 as a treatment for other indications. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause the company’s actual results to be materially different from these forward-looking statements. Raptor cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Factors which may contribute to differences in actual results include, among others: final results of the Phase 2/3 clinical trial of RP103 for the potential treatment of HD; market acceptance and sales of PROCYSBI in the U.S. and the EU; Raptor’s ability to expand the use of RP103 and to receive regulatory approval for other indications; Raptor’s reliance on a single active pharmaceutical ingredient supplier, a single third-party manufacturer and other third parties in connection with drug product development; compliance with healthcare regulations, ongoing regulatory requirements and potential penalties; any serious adverse side effects associated with PROCYSBI or any other future products and product liability claims; third-party payor coverage, reimbursement and pricing; enacted and future healthcare legislation; Raptor’s ability to obtain and maintain orphan drug or other regulatory exclusivity for PROCYSBI or any other future products; the integration of European operations with U.S. operations; relationships with key scientific and medical collaborators; intellectual property protection and claims and continued license rights; and Raptor’s ability to fund its operations and make required payments on its debt. Certain of these risks, uncertainties and other factors are described in greater detail in the company’s filings from time to time with the Securities and Exchange Commission (the “SEC”), which Raptor strongly urges you to read and consider, including: Raptor’s transition report for the four months ended December 31, 2012 on Form 10-KT filed with the SEC on March 14, 2013, as amended, and Raptor’s Quarterly Reports on Form 10-Q filed with the SEC on May 8, 2013, August 9, 2013 and November 7, 2013, which are available free of charge on the SEC’s web site at http://www.sec.gov. Subsequent written and oral forward-looking statements attributable to Raptor or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in Raptor’s reports filed with the SEC. Raptor expressly disclaims any intent or obligation to update any forward-looking statements except as may be required by law.

CONTACT: Georgia Erbez
         Chief Financial Officer
         Raptor Pharmaceutical Corp.
         (415) 408-6231
         gerbez@raptorpharma.com

         INVESTOR CONTACTS:
         Westwicke Partners, LLC
         Robert H. Uhl
         Managing Director
         (858) 356-5932
         robert.uhl@westwicke.com

         MEDIA CONTACT:
         Carolyn Hawley
         Canale Communications
         (619) 849-5375
         carolyn@canalecomm.com

(AAOI) to Participate at Upcoming Investor Conferences

SUGAR LAND, Texas, Feb. 20, 2014  — Applied Optoelectronics, Inc. (Nasdaq:AAOI), a leading provider of fiber-optic access network products for the cable broadband, internet data center, and fiber-to-the-home markets, today announced that management will present at four investor conferences in the month of March.

Presentation webcasts will be available on the investor relations section of the company’s website at investors.ao-inc.com, and the archived version will be available for approximately 30 days.

About Applied Optoelectronics

Applied Optoelectronics Inc. (AOI) is a leading developer and manufacturer of advanced optical products, including components, modules, and equipment. AOI’s products are the building blocks for broadband fiber access networks around the world, where they are used in the CATV broadband, internet datacenter, and fiber-to-the-home markets. AOI supplies optical networking lasers, components and equipment to tier-1 customers in all three of these markets. In addition to its corporate headquarters, wafer fab and advanced engineering and production facilities in Sugar Land, TX, AOI has engineering and manufacturing facilities in Taipei, Taiwan and Ningbo, China. For additional information, visit www.ao-inc.com.

CONTACT: Investor Relations Contacts:
         Applied Optoelectronics, Inc.
         James L. Dunn, Jr.
         Chief Financial Officer
         ir@ao-inc.com

         The Blueshirt Group, Investor Relations
         Maria Riley
         +1-415-217-7722
         ir@ao-inc.com

(JTPY) and LifeMed ID Sign Processing Contract for Medical Services Kiosks

JetPay^® Payment Services, a division of JetPay Corporation (“JetPay” or the “Company”) (NASDAQ:JTPY) and LifeMed ID are pleased to announce an agreement to process financial and data transactions for LifeMed’s patient kiosks.

JetPay is a nationally recognized transaction processor, pre-paid debit card issuer and payroll and tax filing specialist. LifeMed ID is the U.S. industry leader in integrating the use of patient smart cards and biometric devices into the healthcare workflow providing instant, secure and private information exchange between caregivers, medical facilities and patients. LifeMed ID has engaged JetPay as their provider of choice for LifeMed’s newest product — the medical services kiosk. This kiosk is expected to streamline hospital and office check-ins and to provide life-saving data to doctors, as well as allow easy bill payments.

The check in process in non-LifeMed ID-user hospitals and clinics can be a tedious and time consuming process using clipboards, filling out repetitive and, in many cases, redundant forms. Often, there are multiple registrations within the same facility; largely a manual and error prone process. The LifeMed kiosk can now be placed in doctor’s offices and hospitals or clinics to provide a number of key, self-service transactions. Patients can sign-in for appointments using their LifeMed ID which contains all of their patient records and identity verifications. The kiosk can also read and bill from insurance data on the card. Patients can pay their co-pay and finish paperwork items in moments. This frees staff to attend to medical, not regulatory concerns. Strategically placed kiosks for surgical and medical procedure check-ins may eliminate life-threatening mistakes that rely on patients’ memories for important health reporting.

For its part, JetPay customized a solution for the specific needs of LifeMed ID. JetPay offers this flexibility in its payments and processing environment to many companies that require individualized payments options. JetPay is known for providing transparency in its clear statements, fee structure, and attention to the specific needs of their customers’ applications. JetPay is also one of the first processors to offer a one payment scale for all card transactions, including American Express cards.

Trent Voigt, CEO of JetPay Payment Services, commented: “LifeMed processes about $58 million in transactions annually for which we will providing our processing services. We are hoping to expand this relationship quickly as LifeMed ID realizes the benefits of working with one provider for multiple business services. As a vertically integrated provider of business services from payment processing to payroll processing, we can work quickly to solve problems and provide innovative solutions.” He added: “Even more importantly, we believe the LifeMed kiosks, in combination with their ID cards and our transaction processing innovations, may provide a life-saving benefit to consumers.”

David Bachelor, CEO of LifeMed adds: “We selected JetPay due to their ability to customize functionalities to meet our requirements for our kiosks. JetPay already had most of our concerns accounted for, and they custom-built bridges so processing would go smoothly. They also understood the rigorous programming specifications, and expedited the development process to meet our expectations. As a result, we will be live initially in March and fully by July, 2014. We value JetPay’s relationship and their commitment to bringing our kiosk solution to the market.”

Initially, LifeMed ID will be fully automating several hospitals and large doctors’ offices. There are plans to gradually roll out the kiosks to the customer base, which has grown to 200 hospitals in 26 states serving over 3,000,000 patients. There are over 120,000 preventable deaths a year caused by medical mix-ups in paperwork, wrong medications, and wrong procedures. LifeMed ID and JetPay Payment Services hope to have real influence in cutting this number dramatically over the next years. For more information about JetPay solutions, call Shauna Meyer-Reimers, Vice President for VAR sales, at 720-244-0070. For information on LifeMed sales call 916-677-8431 or email at info@lifemedid.com.

About LifeMed ID

LifeMed ID’s Patient Identity company based in Citrus Heights, CA, addresses specific healthcare industry challenges such as confirming patient identity, registration bottlenecks, clipboard registration, duplicate records, registration errors, and an increased need for a higher level of privacy and security. LifeMed ID is the U.S. industry leader in integrating the use of patient Smart cards and biometric devices into the healthcare workflow providing instant, secure and private information exchange between caregivers, medical facilities and patients. This system has proven to dramatically increase patient satisfaction as well as greatly improve operational efficiencies and eliminate costly errors. Patient safety is improved with the virtual elimination of overlaid medical records which is the root cause for erroneous medical procedures and wrong medications.

About JetPay Corporation

JetPay Corporation, based in Berwyn, PA, is a leading provider of vertically integrated solutions for businesses including card acceptance, processing, payroll, payroll tax filing and other financial transactions. JetPay provides a one vendor solution for payment services, debit and credit card processing, ACH services, and payroll and tax processing needs of businesses throughout the U.S. The Company also offers low-cost payment choices for the employees of these businesses to replace costly alternatives. Its vertically aligned services provide customers with convenience and increased revenues by lowering payments-related costs and by designing innovative, customized solutions for internet, mobile, and cloud-based recurring payments.

About JetPay Payment Services

JetPay Payment Services, a division of the JetPay Corporation, headquartered in Carrollton, Texas, a suburb of Dallas, is a premier provider of a front-end and back-end credit card, check, and mobile payments processing, specializing in technology solutions for the e-commerce and card-not-present marketplace. JetPay Payment Services supplies full processing and acquiring services for some of the largest e-commerce sites on the web today. The company offers processing services to banks, sales organizations, and businesses of every size. Please visit www.jetpay.com, www.jetpaycorporation.com, and www.jetpaypayroll.com, for more information on what JetPay has to offer.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. JetPay’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside JetPay’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to, those described under the heading “Risk Factors” in the Company’s latest filed Annual Report on Form 10-K as amended, for the transition period ending December 31, 2012 and the Company’s Quarterly report on Form 10-Q for the quarter ended September 30, 2013.

JetPay cautions that the foregoing list of factors is not exclusive. Additional information concerning these and other risk factors is contained in JetPay’s most recent filings with the Securities and Exchange Commission. All subsequent written and oral forward- looking statements concerning JetPay or other matters and attributable to JetPay or any person acting on its behalf, are expressly qualified in their entirety by the cautionary statements above. JetPay cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. JetPay does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

(EOPN) Hosts Webcast to Discuss Strategies for Maximizing Customer Order Promising

E2open (NASDAQ: EOPN), a leading provider of strategic, cloud-based solutions for collaborative planning and execution across global trading networks, will be sponsoring a webcast featuring customers Avnet Technology Solutions, the global IT solutions distribution leader and an operating group of Avnet, Inc., and Radisys on Tuesday, February 25, 2014, at 2 p.m. (EST) / 11 a.m. (PST). This in-depth panel discussion with two technology industry innovators will focus on best practice approaches to integrate sales and operations planning (S&OP) with short-term order promising and execution, improving profitable fulfillment and customer service.

Moderated by Bob Trebilcock, Editorial Director of Supply Chain Management Review, “Achieving Profitable Customer Fulfillment: Strategies to Maximize Customer Order Promising” will feature Chuck Fries, Vice President, Material Operations at Avnet Technology Solutions, Americas, and Lisa Aleman, Director, Sales and Operations Planning at Radisys. During this presentation, attendees will learn how Avnet and Radisys each developed advanced capabilities to rapidly respond to orders while keeping previous commitments, better understand their constraints to increase order fulfillment, and raise overall profitability.

“By developing strategies to bridge and integrate both short- and long-term goals, Avnet Technology Solutions and Radisys are addressing the missing, and often critical, piece to S&OP process success – collaborative planning and execution,” said Michael Schmitt, Chief Marketing Officer of E2open. “Collaborative planning and execution enables brand owners, suppliers, distributors and customers to commit with confidence and leverage their trading partner network to manage end-to-end supply chain processes and respond intelligently to continuous change. By creating confidence in your customer commits, everybody wins.”

More than 37,000 trading partners and 122,000 unique registered users currently are a part of the E2open Business Network, which allows participants to access and share data and execute business processes in a secure, real-time manner. The E2open Business Network also provides collaboration tools and analytics so that E2open customers can make more informed and efficient decisions.

For more information on E2open, follow us on Twitter at @E2open or visit us on LinkedIn. Join this webinar’s conversation with the hashtag #E2openSCMR.

About E2open

E2open (NASDAQ: EOPN) is a leading provider of cloud-based, on-demand software solutions enabling enterprises to procure, manufacture, sell, and distribute products more efficiently through collaborative planning and execution across global trading networks. Enterprises use E2open solutions to gain visibility into and control over their trading networks through the real-time information, integrated business processes, and advanced analytics that E2open provides. E2open customers include Celestica, Cisco, HGST, HP, IBM, Lenovo, L’Oréal, LSI, Motorola Solutions, Seagate, and Vodafone. E2open is headquartered in Foster City, California with operations worldwide. For more information, visit www.e2open.com.

(STRT) Declares Quarterly Dividend

MILWAUKEE, Feb. 19, 2014  — STRATTEC SECURITY CORPORATION (Nasdaq:STRT) announced today that the Company’s Board of Directors, at its meeting held February 17, 2014, declared a cash dividend for the Company’s 2014 fiscal third quarter of $0.11 per common share. The dividend is payable on March 28, 2014 to shareholders of record as of March 14, 2014.

STRATTEC designs, develops, manufactures and markets automotive Access Control Products, including mechanical locks and keys, electronically enhanced locks and keys, steering column and instrument panel ignition lock housings, latches, power sliding side door systems, power lift gate systems, power deck lid systems, door handles and related products. These products are provided to customers in North America, and on a global basis through a unique strategic relationship with WITTE Automotive of Velbert, Germany and ADAC Automotive of Grand Rapids, Michigan. Under this relationship, STRATTEC, WITTE and ADAC market our products to global customers under the “VAST” brand name. STRATTEC’s history in the automotive business spans over 100 years.

Certain statements contained in this release contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words or phrases such as “anticipate,” “believe,” “could,” “expect,” “intend,” “may,” “planned,” “potential,” “should,” “will,” and “would.”   Such forward-looking statements in this release are inherently subject to many uncertainties in the Company’s operations and business environment. These uncertainties include general economic conditions, in particular, relating to the automotive industry, consumer demand for the Company’s and its customers’ products, competitive and technological developments, customer purchasing actions, foreign currency fluctuations, and costs of operations (including fluctuations in the cost of raw materials). Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances occurring after the date of this release. In addition, such uncertainties and other operational matters are discussed further in the Company’s quarterly and annual filings with the Securities and Exchange Commission.

CONTACT: Pat Hansen
         Senior Vice President and
         Chief Financial Officer
         414-247-3435
         www.strattec.com

(ARWR) Announces Pricing of Underwritten Offering of Common Stock

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced the pricing of an underwritten offering of 5,500,000 shares of its common stock, offered at a price of $18.95 per share. The offering is expected to close on or about February 24, 2014, subject to customary closing conditions. In addition, Arrowhead has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock. Jefferies LLC, Barclays Capital Inc. and Deutsche Bank Securities are acting as joint book-runners for the offering. Piper Jaffray & Co. is acting as lead manager for the offering and Trout Capital acted as a financial advisor to the Company.

Gross offering proceeds will be approximately $104 million, before deducting customary underwriting discounts and commissions and offering expenses. Arrowhead intends to use the net proceeds from this offering for general corporate purposes, including working capital, capital expenditures, research and development expenditures and clinical trial expenditures. A portion of the net proceeds may also be used for the acquisition of complementary businesses, products and technologies, or for other strategic purposes.

The securities described above are being offered pursuant to a shelf registration statement (File No. 333-193748), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on February 12, 2014.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The offering can be made only by means of a prospectus supplement and accompanying prospectus, copies of which may be obtained at the SEC’s website at www.sec.gov, or by request at Jefferies LLC, 520 Madison Avenue, 12th Floor, New York, NY 10022, Attention: Prospectus Department, or by telephone at (877) 547-6340 or by email to Prospectus_Department@Jefferies.com; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, or by telephone at (888) 603-5847, or by email at barclaysprospectus@broadridge.com; or Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, NY 10005-2836, or by telephone at (800) 503-4611, or by email at prospectus.CPDG@db.com.

About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology.

(SHIP) Agreement Restructuring Plan With Final Lender and Approval From Nasdaq

(AMSC) China’s Supreme People’s Court Decides in Favor of AMSC on Jurisdictional Matters

DEVENS, Mass., Feb. 19, 2014 — AMSC (Nasdaq:AMSC), a global solutions provider serving wind and power grid industry leaders, today announced that China’s Supreme People’s Court has decided in favor of AMSC on the jurisdiction of AMSC’s two software copyright infringement cases against Sinovel Wind Group, Ltd. (Sinovel) and Guotong Electric (Guotong). The Supreme People’s Court ruled that the cases will be heard as copyright infringement cases separate from the commercial arbitration claims. The cases will be heard independently in their respective court systems.

These are two of the four legal cases that AMSC brought against Sinovel in late 2011 regarding Sinovel’s contractual breaches and AMSC’s discovery of intellectual property theft by Sinovel. AMSC is also engaged in a commercial arbitration case and a trade secrets case against Sinovel in China.

Background on Beijing Civil Case

In September 2011, AMSC filed a civil action with the Beijing No. 1 Intermediate People’s Court that alleges Sinovel’s unauthorized copying and use of portions of AMSC’s wind turbine control software developed for Sinovel’s 1.5 MW wind turbines and the binary code, or upper layer, of AMSC’s software for its PM3000 power converters. In this case, AMSC is seeking a cease and desist order and damages totaling US$6 million. In November 2011, Sinovel filed a motion to remove this case from the Beijing No. 1 Intermediate People’s Court and transfer the matter to the Beijing Arbitration Commission. The court denied Sinovel’s motion to remove the case. Sinovel filed an appeal of that decision to the Beijing Higher People’s Court, and the Beijing Higher People’s Court supported the Beijing No. 1 Intermediate People’s Court’s ruling and rejected Sinovel’s appeal. Sinovel then filed an appeal of that decision with China’s Supreme People’s Court. The Supreme People’s Court has ruled to uphold the Beijing Higher People’s Court ruling that the dispute shall be heard by the court. AMSC will now await a hearing date from the Beijing No. 1 Intermediate People’s Court.

Background on Hainan Civil Case

In September 2011, AMSC also filed a copyright case against Sinovel and Guotong Electric with the Hainan No. 1 Intermediate People’s Court. In this case, AMSC is seeking a cease and desist order as well as damages totaling approximately US$200,000, making this the smallest of AMSC’s legal actions against Sinovel. In this case, Sinovel filed a jurisdiction opposition motion in December 2011 requesting that the Hainan No. 1 Intermediate People’s Court dismiss AMSC’s case against Sinovel, saying the case should be governed by the Beijing Arbitration Commission pursuant to the terms of component contracts between AMSC and Sinovel. Not only did the court grant Sinovel’s motion, but also it dismissed the cases against both Sinovel and Guotong. AMSC appealed the dismissal to the Hainan Higher People’s Court, which on April 5, 2012 upheld the decision of the Hainan No. 1 Intermediate People’s Court. AMSC then filed an appeal of that decision with China’s Supreme People’s Court. The Supreme People’s Court overturned the previous two rulings made by the Hainan No. 1 Intermediate People’s Court and Hainan Higher People’s Court and has ruled that the case will be heard by the court. AMSC will now await a hearing date from Hainan No. 1 Intermediate People’s Court.

About AMSC (NASDAQ: AMSC)

AMSC generates the ideas, technologies and solutions that meet the world’s demand for smarter, cleaner … better energy. Through its Windtec™ Solutions, AMSC provides wind turbine electronic controls and systems, designs and engineering services that reduce the cost of wind energy. Through its Gridtec™ Solutions, AMSC provides the engineering planning services and advanced grid systems that optimize network reliability, efficiency and performance. The company’s solutions are now powering gigawatts of renewable energy globally and enhancing the performance and reliability of power networks in more than a dozen countries. Founded in 1987, AMSC is headquartered near Boston, Massachusetts with operations in Asia, Australia, Europe and North America. For more information, please visit http://www.amsc.com.

AMSC, Windtec and Gridtec are trademarks or registered trademarks of American Superconductor Corporation. All other brand names, product names, trademarks or service marks belong to their respective holders.

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Any statements in this release about future expectations, plans, prospects, and our beliefs regarding the potential impact of the Supreme People’s Court ruling on AMSC’s other pending cases against Sinovel and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements represent management’s current expectations and are inherently uncertain.

There are a number of important factors that could materially impact the value of our common stock or cause actual results to differ materially from those indicated by such forward-looking statements. Such factors include: We have experienced recurring operating losses and recurring negative cash flows from operations which raise substantial doubt about our ability to continue as a going concern. This substantial doubt has resulted in a qualified opinion from our auditors with an explanatory paragraph regarding our ability to continue as a going concern. We believe this opinion may have an adverse effect on our customer and supplier relationships; our success in addressing the wind energy market is dependent on the manufacturers that license our designs; we may not realize all of the sales expected from our backlog of orders and contracts; our business and operations would be adversely impacted in the event of a failure or security breach of our information technology infrastructure; our success is dependent upon attracting and retaining qualified personnel and our inability to do so could significantly damage our business and prospects; we rely upon third-party suppliers for the components and subassemblies of many of our Wind and Grid products, making us vulnerable to supply shortages and price fluctuations, which could harm our business; many of our revenue opportunities are dependent upon subcontractors and other business collaborators; if we fail to implement our business strategy successfully, our financial performance could be harmed; problems with product quality or product performance may cause us to incur warranty expenses and may damage our market reputation and prevent us from achieving increased sales and market share; new regulations related to conflict-free minerals may force us to incur significant additional expenses; our contracts with the U. S. government are subject to audit, modification or termination by the U.S. government and include certain other provisions in favor of the government; the continued funding of such contracts remains subject to annual congressional appropriation which, if not approved, could reduce our revenue and lower or eliminate our profit; we may acquire additional complementary businesses or technologies, which may require us to incur substantial costs for which we may never realize the anticipated benefits; many of our customers outside of the United States are, either directly or indirectly, related to governmental entities, and we could be adversely affected by violations of the United States Foreign Corrupt Practices Act and similar worldwide anti-bribery laws outside the United States; we have limited experience in marketing and selling our superconductor products and system-level solutions, and our failure to effectively market and sell our products and solutions could lower our revenue and cash flow; we have experienced recurring losses from operations and negative operating cash flow; these factors raise substantial doubt regarding our ability to continue as a going concern; we have a history of operating losses, and we may incur additional losses in the future; our operating results may fluctuate significantly from quarter to quarter and may fall below expectations in any particular fiscal quarter; we may require additional funding in the future and may be unable to raise capital when needed; our debt obligations include certain covenants and other events of default;. Should we not comply with the covenants or incur an event of default, we may be required to repay our debt obligations in cash, which could have an adverse effect on our liquidity; if we fail to maintain proper and effective internal controls over financial reporting, our ability to produce accurate and timely financial statements could be impaired and may lead investors and other users to lose confidence in our financial data; we may be required to issue performance bonds or provide letters of credit, which restricts our ability to access any cash used as collateral for the bonds or letters of credit; changes in exchange rates could adversely affect our results from operations; growth of the wind energy market depends largely on the availability and size of government subsidies and economic incentives; we depend on sales to customers in China and India, and global conditions could negatively affect our operating results or limit our ability to expand our operations outside of these countries; changes in China’s or India’s political, social, regulatory and economic environment may affect our financial performance; our products face intense competition, which could limit our ability to acquire or retain customers; our international operations are subject to risks that we do not face in the United States, which could have an adverse effect on our operating results; adverse changes in domestic and global economic conditions could adversely affect our operating results; we may be unable to adequately prevent disclosure of trade secrets and other proprietary information; our patents may not provide meaningful protection for our technology, which could result in us losing some or all of our market position; the commercial uses of superconductor products are limited today, and a widespread commercial market for our products may not develop; there are a number of technological challenges that must be successfully addressed before our superconductor products can gain widespread commercial acceptance, and our inability to address such technological challenges could adversely affect our ability to acquire customers for our products; we have not manufactured our Amperium wire in commercial quantities, and a failure to manufacture our Amperium wire in commercial quantities at acceptable cost and quality levels would substantially limit our future revenue and profit potential; third parties have or may acquire patents that cover the materials, processes and technologies we use or may use in the future to manufacture our Amperium products, and our success depends on our ability to license such patents or other proprietary rights; our technology and products could infringe intellectual property rights of others, which may require costly litigation and, if we are not successful, could cause us to pay substantial damages and disrupt our business; we have filed a demand for arbitration and other lawsuits against our former largest customer, Sinovel, regarding amounts we contend are overdue. We cannot be certain as to the outcome of these proceedings; we have been named as a party to purported stockholder class actions and stockholder derivative complaints, and we may be named in additional litigation, all of which will require significant management time and attention, result in significant legal expenses and may result in an unfavorable outcome, which could have a material adverse effect on our business, operating results and financial condition; our 7% convertible note contains warrants and provisions that could limit our ability to repay the note in shares of common stock and should the note be repaid in stock, shareholders could experience significant dilution; our common stock has experienced, and may continue to experience, significant market price and volume fluctuations, which may prevent our stockholders from selling our common stock at a profit and could lead to costly litigation against us that could divert our management’s attention. These and the important factors discussed under the caption “Risk Factors” in Part 1. Item 1A of our Form 10-K for the fiscal year ended March 31, 2013, and our other reports filed with the SEC, among others, could cause actual results to differ materially from those indicated by forward-looking statements made herein and presented elsewhere by management from time to time. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

CONTACT: AMSC Contact:
         Kerry Farrell
         Phone: 978-842-3247
         Email: kerry.farrell@amsc.com

(OCLS) Receives Approval for Oral and Throat Infection Products in Mexico

Latin American Partner, More Pharma, to Launch First Oral Care Products in Spring 2014

PETALUMA, Calif., Feb. 19, 2014  — Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 31 countries, today announced a regulatory approval in Mexico for the company’s new Microcyn60® Oral Care family of products intended for use as an adjunct treatment in both mouth and throat infections.

Bruce Thornton, executive vice president of Oculus, said: “This is an extremely exciting time for Oculus since it’s the first Microcyn-based product approved anywhere in the world for the antiseptic treatment of both mouth and throat infections. The commercialization of our Microcyn Technology for this promising new indication lays the foundation for its introduction into other international markets, in particular Europe. As we did with our recent Mexican approval of Microcyn for acne, we will leverage this Mexican approval for oral care by using the approved dossier in our submission to the European notified body for CE Mark approval. This two-step approach to regulatory submissions provides us the opportunity to migrate these new products to Europe in the quickest time possible.”

The first oral care product to be launched by Oculus’ Latin American partner, More Pharma, will be Microdacyn60 Bucofaringeo. The More Pharma sales team intends to target general practitioners as well as ear, nose and throat specialists in mid-2014, enlightening these healthcare professionals to the advantages of Microdacyn60 Bucofaringeo well in advance of the 2014 fall/winter cold and flu season.

Guillermo Ibarra, More Pharma’s CEO, said, “With global concerns about the overuse and misuse of antibiotics in the treatment of pathogen-related infections, a safe and effective oral antiseptic such as Microdacyn60 Bucofaringeo, which doesn’t facilitate antibiotic resistance, will be warmly received by the Mexican healthcare community. We take great pride in helping lead in this effort to reduce the incidence of growing antibiotic-resistant strains of bacteria while also improving health outcomes. In addition to Mexico, we will also move as rapidly as we are able to introduce Microdacyn60 Bucofaringeo into other Latin American countries.”

About Oculus Innovative Sciences

Oculus Innovative Science is a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 31 countries. The company’s products are used to treat patients in surgical/advanced wound management, dermatology, women’s health and animal health; addressing the unmet medical needs of these markets—while raising the standard of patient care and lowering overall healthcare costs. The company’s headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. More information can be found at www.oculusis.com.

About More Pharma

Founded in 2007, More Pharma is a pharmaceutical company with strong growth performance and a team of more than 300 people. The company has a talented sales and marketing team with significant prior experience with large international pharmaceutical companies. They have ample funding and support by their renowned financial sponsors, Southern Cross Group and Evercore, both of which manage more than $1 billion of venture funds. The company is dedicated to finding solutions to healthcare challenges via product development, in-licensing and product acquisitions. With headquarters in Mexico City, More Pharma has a presence in Mexico, Latin America and the Caribbean. More information can be found at www.morepharmacorp.com/eng/index.php.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the Company’s commercial and technology progress and future financial performance. These forward-looking statements are identified by the use of words such as “growth,” “expansion” and “build,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, and its ability to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including the annual report on Form 10-K for the year ended March 31, 2013. Oculus Innovative Sciences disclaims any obligation to update these forward-looking statements except as required by law.

Oculus and Microcyn Technology are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.

CONTACT: Media and Investor Contact:
         Oculus Innovative Sciences, Inc.
         Dan McFadden
         VP of Public and Investor Relations
         (425) 753-2105

(INOD) RGA Announces Strategic Relationship With Synodex

(MYGN) Publishes Prolaris® Data in the Journal of Urology

SALT LAKE CITY, Feb. 18, 2014  — Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it has published data in the Journal of Urology demonstrating that its Prolaris test accurately predicted, based on biopsy specimens, which men would develop biochemical recurrence (BCR) or metastatic disease following radical prostate surgery. Prolaris is a 46-gene molecular diagnostic test that has been evaluated in more than 5,000 patients across 11 clinical studies.

“This study represents a great advance in the treatment of prostate cancer. The results from three different institutions show that Prolaris can better define patient prognosis and improve care,” said Jay T. Bishoff, M.D., director of the Intermountain Urological Institute, at Intermountain Health Care and a study investigator. “Having a test that identifies which patients are likely to fail surgery is a big clinical advantage for physicians. Patients with a low score may be candidates for active surveillance, while patients with a high score indicative of aggressive cancer, may benefit from more intensive medical treatments.”

The study evaluated biopsy specimens in 582 men who were treated by radical prostatectomy. In the study, biopsy samples were evaluated from three cohorts of contemporary patients in the United States and Germany. The clinical endpoints were metastatic disease and BCR. In all cohorts, the Prolaris test was a statistically significant predictor of BCR and was the single strongest predictor of metastatic disease when compared to Gleason Score or PSA. In the pooled analysis, each one-unit increase in the Prolaris score translated into a fivefold increased risk of metastases and a 1.6-times increased risk of BCR.

“Men newly diagnosed with prostate cancer are often treated by radical prostatectomy, and about 30 percent of these patients will have metastases or progress even after surgery,” said Michael Brawer, M.D., vice president of medical affairs at Myriad Genetic Laboratories. “The Prolaris test answers an important clinical question for all urologists concerning their surgical candidates…do my patients have an aggressive prostate cancer or not and therefore need more aggressive treatment?”

About Prolaris^®

Prolaris is a novel 46-gene RNA-expression test that directly measures tumor cell growth characteristics for stratifying the risk of disease progression in prostate cancer patients. Prolaris provides a quantitative measure of the RNA expression levels of genes involved in the progression of tumor growth. Low gene expression is associated with a low risk of disease progression in men who may be candidates for surveillance and high gene expression is associated with a higher risk of disease progression in patients who may benefit from additional therapy. Prolaris has been proven to predict prostate cancer-specific disease progression in 11 clinical trials with more than 5,000 patients. For more information visit: www.prolaris.com and www.myriad.com/understanding-prostate-cancer/.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients’ lives through the discovery and commercialization of transformative tests to assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad’s molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual’s decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company’s website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, Melaris, Myriad myPath, Myriad myPlan, Myriad myRisk, TheraGuide, Prezeon, Panexia, and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Prolaris clinical study data; the effectiveness of Prolaris testing to accurately predict cancer-specific disease progression including metastases and biochemical recurrence; and the Company’s strategic directives under the caption “About Myriad Genetics”. These “forward-looking statements” are management’s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and companion diagnostic services may decline or will not continue to increase at historical rates; risks related to changes in the governmental or private insurers reimbursement levels for our tests; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and companion diagnostic services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and companion diagnostic services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and companion diagnostic services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to increased competition and the development of new competing tests and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and companion diagnostic services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading “Risk Factors” contained in Item 1A of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

CONTACT: Media Contact:

         Ron Rogers
         (801) 584-3065
         rrogers@myriad.com

         Investor Contact:

         Scott Gleason
         (801) 584-1143
         sgleason@myriad.com

(JASO) Multi-Si Solar Cells Surpass 19% Conversion Efficiency

SHANGHAI, China, Feb. 18, 2014  — JA Solar Holdings Co., Ltd. (Nasdaq:JASO) (“JA Solar” or the “Company”), one of the world’s largest manufacturers of high-performance solar power products, today announced that its multi-crystalline silicon (“multi-Si”) solar cells have surpassed 19% conversion efficiency.

This latest improvement in efficiency, achieved using advanced cell technology recently developed by JA Solar’s R&D team, follows the Company’s announcement in August 2013 that its multi-Si cells had achieved 18.3% conversion efficiency, an industry record at the time.

“By breaking the 19% efficiency barrier with our multi-Si cells, JA Solar has reached yet another milestone in terms of our ability to produce high-performance solar products in a cost-effective manner,” said Mr. Yong Liu, chief operation officer of JA Solar. “The new cells are a further testament to JA Solar’s unrivaled efforts to push the boundaries of PV technology, and their superior power generation per unit of area and lower installation cost per watt will deliver significant value to customers.”

JA Solar plans to commence mass production of its new multi-Si cells and integrate them into module assembly lines for commercial use in the second half of 2014.

Forward-looking Statements

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words such as “may,” “expect,” “anticipate,” “aim,” “intend,” “plan,” “believe,” “estimate,” “potential,” “continue,” and other similar statements. Statements other than statements of historical facts in this announcement are forward-looking statements, including but not limited to, our expectations regarding the expansion of our manufacturing capacities, our future business development, and our beliefs regarding our production output and production outlook. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company and the industry. Further information regarding these and other risks is included in Form 20-F and other documents filed with the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that its expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results.

About JA Solar Holdings Co., Ltd.

JA Solar Holdings Co., Ltd. is a leading manufacturer of high-performance solar power products that convert sunlight into electricity for residential, commercial, and utility-scale power generation. The Company is one of the world’s largest producers of solar power products. Its standard and high-efficiency product offerings are among the most powerful and cost-effective in the industry. The Company distributes products under its own brand and also produces on behalf of its clients. The Company shipped 1.7 GW of solar power products in 2012. JA Solar is headquartered in Shanghai, China, and maintains production facilities in Shanghai, as well as Hebei, Jiangsu and Anhui provinces.

For more information, please visit www.jasolar.com.

CONTACT: In China

         Nick Beswick
         Brunswick Group
         Tel: +86-10-5960-8600
         E-mail: jasolar@brunswickgroup.com

         In the U.S.

         Cindy Zheng
         Brunswick Group
         Tel: +1-212-333-3810
         E-mail: jasolar@brunswickgroup.com

(PCOM) MasterCard Teams With Points International to Offer Cardholders Enhanced Rewards

Issuing Banks Gain Opportunities to Deliver Greater Flexibility to Consumers Through Exchange and Trade of Airline Miles, Hotel Points and Other Loyalty Currencies

TORONTO and PURCHASE, N.Y., Feb. 18, 2014  — MasterCard (NYSE:MA) today enhanced its rewards capabilities for cardholders, giving them more ways to redeem, exchange and trade their rewards points.

These unique capabilities, unavailable to consumers that are members of current credit card-based rewards programs, will be delivered through a relationship between MasterCard and Points International Ltd. (TSX:PTS) (Nasdaq:PCOM). Based on the popularity of travel and experiences, the enhanced rewards management and monetization options are expected to drive engagement and value to rewards programs offered by issuing banks participating in the MasterCard Rewards Platform.

“Consumers have said loudly and clearly that they want increased flexibility with their rewards,” said Nandan Mer, Group Executive, MasterCard Loyalty Solutions. “Our enhanced solution delivers just that – the ability to exchange, trade, buy and gift rewards points. We believe this truly unique and superior redemption experience delivers even more value to all involved.”

“While the financial services industry has been a keen focus for some time, we are especially excited to be partnering with a leading organization like MasterCard,” commented Rob MacLean, Chief Executive Officer, of Points. “Together, we are enhancing and differentiating issuer rewards programs hosted on the MasterCard Rewards Platform and making them more attractive to consumers.”

Following the initial integration, it is anticipated that program functionality will be available later this year.

About MasterCard

MasterCard (NYSE:MA), www.mastercard.com, is a technology company in the global payments industry. We operate the world’s fastest payments processing network, connecting consumers, financial institutions, merchants, governments and businesses in more than 210 countries and territories. MasterCard’s products and solutions make everyday commerce activities – such as shopping, traveling, running a business and managing finances – easier, more secure and more efficient for everyone. Follow us on Twitter @MasterCardNews, join the discussion on the Cashless Pioneers Blog and subscribe for the latest news on the Engagement Bureau.

About Points

Points, publicly traded as Points International Ltd. (TSX:PTS) (Nasdaq:PCOM), is the global leader in loyalty currency management. Via a state-of-the-art loyalty commerce platform, Points provides loyalty eCommerce and technology solutions to the world’s top brands to enhance their consumer offerings and streamline their back-end operations.

Points’ solutions enhance the management and monetization of loyalty currencies ranging from frequent flyer miles and hotel points to retailer and credit card rewards, for more than 45 partners worldwide. Points also manages Points.com, where almost 4 million consumers use the only industry sanctioned loyalty wallet to not only track all of their loyalty programs but also trade, exchange and redeem their miles and points. In addition to these services, Points’ unique SaaS products allow eCommerce merchants to add loyalty solutions directly to their online stores, rewarding customers for purchases at the point-of-sale.

Points has been widely recognized among the loyalty and technology communities alike. The Company was named the 4th largest Canadian software company and the 40th largest Canadian technology company by the 2013 Branham300 list. Points also ranked 40th among PROFIT Magazine’s top 200 Canadian companies by five-year revenue growth. For more information on Points, please visit www.Points.com, follow us @PointsBiz on Twitter or read the Points Loyalty News blog.

CONTACT: Media Contacts
         Brian Gendron
         MasterCard Worldwide
         914-249-1284
         brian_gendron@mastercard.com

         Danielle Mason
         ThinkInk PR, for Points Public Relations
         305-749-5342 x235 or 416-628-9684
         dmason@thinkinkpr.com

         Laura Bainbridge/Kimberly Esterkin
         Addo Communications, for Points Investor Relations
         310-829-5400
         laurab@addocommunications.com; kimberlye@addocommunications.com

(LTBR) Obtains Key U.S. Patent for Its Safe Nuclear Metallic Fuel Design

New Technology Designed to Help Usher in New Era of Safe Nuclear Power Generation

MCLEAN, Va., Feb. 18, 2014  — Lightbridge Corporation (Nasdaq:LTBR), a leading innovator of nuclear fuel designs and provider of nuclear energy consulting services, today announced that the U.S. Patents and Trademarks Office (USPTO) has approved and issued to Lightbridge the key patent covering Lightbridge’s multi-lobed metallic fuel rod design and fuel assemblies. The patent number is 8,654,917 and is available on the USPTO website at http://www.uspto.gov/.

“This new patent is the single most important patent in Lightbridge’s intellectual property portfolio and is crucial to the Company’s future royalty revenue stream,” said Seth Grae, President and Chief Executive Officer. “We now have very broad protection for the metal fuel element that will be used in all of our fuel assembly designs. Moreover, this successful outcome secures patent protection in the U.S. – the world’s largest market of pressurized water reactors currently in operation.”

Lightbridge is developing and commercializing next generation nuclear fuel technology with benefits of improving the safety and economics of existing and new light water reactors. The Company has filed equivalent patent applications that are pending approval in several key countries in Europe and Asia.

“Lightbridge continues to achieve its major developmental milestones through the dedicated, significant high technology work of our extremely skilled team of nuclear engineers,” Grae said. “We expect our success will translate into one or more teaming arrangements with major nuclear fuel fabricators and other strategic partners that may include cost-sharing contributions or revenue in the form of technology access fees to Lightbridge based on our intellectual property, as well as engineering support services.”

In October 2013 the Company announced that it had signed a memorandum of understanding with the Babcock & Wilcox Company (NYSE:BWC) to evaluate constructing a pilot-scale fuel fabrication facility to demonstrate fabrication of Lightbridge-designed metallic fuel rods up to full length.

Unlike conventional fuel rods comprised of uranium oxide pellets that are stacked in zirconium alloy tubes, Lightbridge’s proprietary multi-lobed metallic fuel rods are a solid uranium-zirconium alloy, extruded in full size lengths of 12 to 14 feet.

“Lightbridge’s unique metallic fuel technology presents a compelling value proposition to a growing global industry,” said James P. Malone, Lightbridge Chief Nuclear Fuel Development Officer. “Our patented metallic fuel rod design offers increased structural integrity and improved heat transfer while operating at nearly 1,000ºC cooler than conventional rods. It will deliver 10% to 17% more power from existing light water reactors and longer fuel cycles to nuclear utilities. These benefits will enhance safety, increase revenue and improve operating margins for both existing power units and new-build commercial reactors.”

For a more detailed description of the value proposition of Lightbridge fuel technology, including projected incremental annual net operating cash flows and return on investment for a nuclear power plant operator at various wholesale electricity prices, visit http://bit.ly/1jLXpoY

The benefits of Lightbridge’s metallic fuel design were confirmed in three independent third-party analyses published in 2012 and 2013. These analyses, which include a peer-reviewed article published in Nuclear Technology, are available for download at http://ir.ltbridge.com/.

The unique geometry of Lightbridge metallic fuel rods is illustrated in the following slide, featuring actual and schematic cross sections, as well as a test fuel assembly. Cross sections of conventional uranium oxide fuel rods and Lightbridge’s metallic fuel rod are compared in the second illustration.

http://www.globenewswire.com/newsroom/prs/?pkgid=23650

http://www.globenewswire.com/newsroom/prs/?pkgid=23651

About Lightbridge Corporation

Lightbridge is a US nuclear energy company based in McLean, Virginia with operations in Abu Dhabi, Moscow and London. The Company develops proprietary, proliferation resistant, next generation nuclear fuel technologies for current and future nuclear reactor systems. The Company also provides comprehensive advisory services for established and emerging nuclear programs based on a philosophy of transparency, non-proliferation, safety and operational excellence. Lightbridge’s breakthrough fuel technology is establishing new global standards for safe and clean nuclear power and leading the way to a sustainable energy future. Lightbridge consultants provide integrated strategic advice and expertise across a range of disciplines including regulatory affairs, nuclear reactor procurement and deployment, reactor and fuel technology and international relations. The Company leverages those broad and integrated capabilities by offering its services to commercial entities and governments with a need to establish or expand nuclear industry capabilities and infrastructure.

Lightbridge is on Twitter. Sign up to follow @LightbridgeCorp at http://twitter.com/lightbridgecorp.

Forward Looking Statements

This news release contains statements that are forward-looking in nature within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s competitive position and product and service offerings. These statements are based on current expectations on the date of this news release and involve a number of risks and uncertainties that may cause actual results to differ significantly from such estimates. The risks include, but are not limited to, the degree of market adoption of the Company’s product and service offerings; market competition; dependence on strategic partners; and the Company’s ability to manage its business effectively in a rapidly evolving market. Certain of these and other risks are set forth in more detail in Lightbridge’s filings with the Securities and Exchange Commission. Lightbridge does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise.

CONTACT: MEDIA AND INVESTOR CONTACTS:
         Gary Sharpe
         Lightbridge Corporation
         1-571-730-1213
         gsharpe@ltbridge.com

         Fred Bona/Rob Swadosh
         The Dilenschneider Group
         1-212-922-0900
         fbona@dgi-nyc.com
         rswadosh@dgi-nyc.com

(PRAN) Meets Primary Endpoint in Phase 2 Huntington Disease REACH2HD Clinical Study

MELBOURNE, Australia and NEW YORK, Feb. 18, 2014 —

Key Points:

• Primary endpoints of safety and tolerability met.
• Secondary endpoint: Statistically significant improvement in a measure of executive function(cognition) in research participants administered 250mg PBT2 daily (p=0.042).
• PBT2 250mg was also associated with a favourable signal in functional capacity.  
• Preliminary evidence suggests PBT2 250mg reduced atrophy of brain tissue in areas affected in Huntington disease, seen in a pilot imaging sub-study.
• Company plans to advance PBT2 to a confirmatory Phase 3 clinical trial.
• Prana to host investor conference call and webcast today at 5:30pm ET; See access information below

Prana Biotechnology (ASX:PBT; NASDAQ:PRAN) today announced that its Phase 2 REACH2HD clinical trial investigating PBT2 as a treatment for Huntington disease met its primary safety endpoint and achieved statistically significant improvement in a measure of executive function (cognition), which comprised part of the study’s main efficacy outcome. Prana plans to advance PBT2 into a confirmatory Phase 3 clinical trial that could allow PBT2 to be approved for the treatment of Huntington disease.

Dr. Ray Dorsey, Professor of Neurology at the University of Rochester and the Principal Investigator on the trial added: “We are very pleased that the results of the Reach2HD study have shown that PBT2 is well tolerated and generally safe over six months in individuals with early to mid-stage Huntington disease.”

“In addition, the results indicated a significant benefit on cognition that is consistent with the previous trial in Alzheimer’s disease and is accompanied by an encouraging finding in functional capacity. We are very thankful for the involvement of the research participants and investigators in this study and look forward to future trials of this promising therapy for one of the cardinal features of Huntington disease.”

Reach2HD is a double-blind, placebo-controlled study was conducted by the Huntington Study Group at research sites in the United States and Australia. The study enrolled 109 individuals with Huntington disease who were randomly assigned to receive daily doses of either PBT2 250mg, PBT2 100mg, or placebo for 26 weeks.

The primary endpoint of the study was met. In this study, PBT2 was safe and well tolerated. Ninety-five percent (104 of 109) of participants completed the study on their assigned dose. There were no substantial differences in adverse events across the two PBT2 dose groups and the placebo group. Only one of the ten reported serious adverse events was deemed by the clinical site investigator to be related to drug treatment.

An independent Data Safety Monitoring Board met on five occasions over the course of the trial and on each occasion recommended that the trial continue as per the original protocol.

The effects of PBT2 were tested on cognition, motor performance, behaviour and functional capacity, of which cognition was pre-specified as the main efficacy outcome.

There was a statistically significant improvement in performance on the Trail Making Test Part B, in the PBT2 250mg group compared to placebo at both 12 (p<0.001) and 26 weeks (p=0.042). Trail Making Test Part B is a measure of executive function (e.g., ability to plan activities), which is impaired early in the course of Huntington disease and is also affected in Alzheimer’s disease.

Given the evidence from an earlier trial that showed that PBT2 improved executive function in Alzheimer’s disease patients, the Reach2HD trial included a plan to assess the effects of PBT2 on an Executive Function Composite z-score that included the Trail Making Test Part B. There was a statistically significant improvement in this z-score (p=0.038) in a pre-specified analysis of Reach2HD participants with early stage Huntington disease, as measured by their Total Functioning Capacity score. Across all participants, which comprised both early and mid-stage patients, there was a trend to improvement (p=0.069).

Dr. Rudy Tanzi, Professor of Neurology at Harvard Medical School and Prana’s Chief Scientific Advisor, said: “The observation of significant improvement in executive function with PBT2 in this clinical trial for Huntington disease and the previously reported Alzheimer’s trial, suggests a common mechanism for neurodegeneration in these diseases based on metal interactions. In my opinion, these findings significantly elevate the potential for PBT2 as an effective therapy for both Huntington disease and Alzheimer’s disease.”

The improvement in executive function was accompanied by a small but favourable signal in a key measure of functional capacity.

Dr. Ira Shoulson, Professor of Neurology at Georgetown University and Chair of the Huntington Study Group, who was not involved in the trial and acts as an advisor to Prana, added: “In the Reach2HD trial, the improvement in executive function performance was also accompanied by a favourable signal of a slowing of functional decline, as measured by the Total Functional Capacity score. This is the first time we have observed dose-related slowing in functional decline over a six month period of treatment – which taken together with the safety reassurance –  will provide genuine optimism for the Huntington disease community to support a larger confirmatory trial of PBT2 in Huntington disease.”

Finally, as Huntington disease and other neurodegenerative disorders progress, there is a gradual loss of brain tissue or atrophy. In Reach2HD, brain imaging using magnetic resonance imaging (MRI) was performed in a small subset of patients (n=6) to map anatomical changes in brain structure. In the combined PBT2 groups (n=4) a reduction in atrophy  of brain tissue in regions of the brain known to be affected by Huntington disease was observed compared to the placebo group.

Dr. Diana Rosas, Associate Professor of Neurology at Harvard Medical School and the study’s co-Principal Investigator who conducted the imaging sub-study commented: “Despite the very small number of patients in the sub-study, the data are suggestive of a beneficial effect of PBT2 in regions of the brain that are known to be vulnerable to Huntington disease.”

A detailed clinical announcement is available on the Company’s web site at www.pranabio.com. For patient enquiries please contact huntingtons@pranabio.com or call 1300 13 90 33.

Investor Conference Call Information:
Prana will host an investor conference call and webcast this evening at 5:30pm Eastern Time to discuss the study results.  Investors in the United States may access the conference call by dialing 1 (855) 293-1544; conference ID: 58817510.  The live webcast may be accessed here.  Additional conference call information is available at www.pranabio.com, including Australian and international conference numbers.

Due to the expected high number of participants on the call, we recommend you commence registration for the event 15 minutes prior.   A recording of the call will be available within 4 hours of its conclusion and will remain available for three months.  The archived recording can be accessed here.

(RJET) Airways Reaches Tentative Agreement with Its Pilot Union

Republic Airways Holdings (NASDAQ: RJET) today announced that it has reached a Tentative Agreement (TA) on a new four-year contract with the International Brotherhood of Teamsters (IBT) Local 357. Local 357 represents more than 2,200 pilots for sister companies Chautauqua Airlines, Republic Airlines and Shuttle America.

The proposed contract includes increases in pay that will place Republic pilots at or near the top of its airline peers. It also includes improvements in work rules, quality of life enhancements and more flexibility in scheduling as well as a significant signing bonus if ratified. The TA still must be presented to union members for review and a formal ratification vote, which is expected in March.

“We are extremely pleased that we have, at long last, reached a new working agreement that recognizes the significant contributions our pilots make to our continued success. Every day, our flight crews deliver on Republic’s brand promise of providing the safest and most reliable flight service for our major airline partners,” said Republic Airways Executive Vice President and Chief Operating Officer Wayne Heller. “This TA has the economics that make it possible for the Company to provide our pilots with an industry-leading working agreement, while at the same time allowing Republic to remain competitive as we pursue new business opportunities.”

Captain David Bourne, Director of IBT’s Airline Division, commented, “This agreement reflects a hard-earned and well deserved achievement for the enhancement of pay and work conditions for the Republic pilot group.”

“At a time when many of our competitors are moving in the opposite direction on pilot compensation, we are thrilled that Republic is able to significantly improve the wages and benefits of the more than 2,200 women and men who safely fly more than 1,300 daily scheduled flights for our major airline partners,” said Bryan Bedford, Chairman, President and Chief Executive Officer of Republic Airways. “In August of this year, we will celebrate 40 years of commercial flight. So it is especially gratifying at this important milestone that we can recognize and thank our pilots for their contribution in maintaining our perfect passenger safety record for four decades.”

“This TA reflects the dedication and hard work of the Union and the Company’s negotiating committees,” Heller said. “We thank the Union representatives for their professionalism and commitment in reaching this agreement.”

Republic Airways Holdings, based in Indianapolis, Indiana, is an airline holding company that owns Chautauqua Airlines, Republic Airlines and Shuttle America, collectively “the airlines.” The airlines operate a combined fleet of approximately 250 aircraft and offer scheduled passenger service on over 1,350 flights daily to more than 110 cities in the U.S., Canada and the Bahamas through fixed-fee flights operated under our major airline partner brands, including American Eagle, Delta Connection, United Express, and US Airways Express. The airlines currently employ about 6,000 aviation professionals. For more information on Republic Airways, please visit our website at www.rjet.com.

(SHPG) FDA Approval of Manufacturing Facility for VPRIV®

Investor Relations: Eric Rojas, erojas@shire.com, +1-781-482-0999; Sarah Elton-Farr, seltonfarr@shire.com, +44-1256-894157; Media: Jessica Mann, jmann@shire.com, +44-1256-894-280; Gwen Fisher, gfisher@shire.com, +1-484-595-9836; Jessica Cotrone, jcotrone@shire.com, +1-781-482-9538Copyright CNW Group 2014

(EVI) Announces Improved Revenues and Earnings for the Second Quarter

EnviroStar, Inc., (NYSE MKT: EVI), today reported improved operating results for the six and three month periods ended December 31, 2013. For the first six months of fiscal 2014, revenues increased by 41.4% to $18,328,643 from $12,958,823 for the same period of fiscal 2013. Net earnings increased by 226.0% to $903,077 or $.13 per share compared to net income of $276,994 or $.04 per share for the same period of fiscal 2013.

For the second quarter of fiscal 2014, revenues increased by 52.6% to $9,835,413 from $6,445,709 in the comparable period of fiscal 2013. Net earnings for the period increased by 281.4% to $477,306 or $.07 per share compared to $125,155 or $.02 per share for the second quarter of fiscal 2013.

Venerando J. Indelicato, Chief Financial Officer of EnviroStar Inc., stated, “We are pleased with the Company’s performance for the six and three month periods of fiscal 2014. As already reported, we began the year with a solid backlog and we projected fiscal 2014 to be a successful year. At this point in time these projections are on track, although individual quarters may differ depending on future scheduling.”

EnviroStar, Inc. through its subsidiaries is one of the nation’s leading distributors of industrial laundry, dry cleaning equipment and steam boilers.

This press release contains certain information that is subject to a number of known and unknown risks and uncertainties that may cause actual results and trends to differ materially from those expressed or implied by the forward-looking statements. Information concerning those factors are discussed in Company reports filed with the Securities and Exchange Commission.

(EXTR) Appoints Eric Broockman as Vice President and Chief Technology Officer

SANTA CLARA, Calif., Feb. 14, 2014  — Extreme Networks, Inc. (NASDAQ: EXTR), a leader in high performance networking, today announced the appointment of Eric Broockman as Vice President and Chief Technology Officer (CTO). Broockman will be based at the company’s headquarters in San Jose, California.

Broockman is an accomplished technology executive having held CEO and GM roles over the last 25 years. Broockman’s experience includes R&D and business strategy for large and private technology companies spanning a breadth of network products, including Ethernet LAN switching, wireless, core routers, and networking software.

“Eric brings leadership and an impressive vision for innovation that will benefit Extreme Networks as we expand and evolve our industry-leading network solutions,” said Chuck Berger, president and CEO for Extreme Networks.

“The industry is entering a period of extraordinary change as a result of emerging technology inflection points,” said Broockman. “Extreme Networks is well positioned to capitalize on these market shifts within high impact segments for switching, high performance Wi-Fi­ access, data center, security, software products, SDN and network visibility and management.”

Broockman’s depth of industry experience includes executive management roles for technology leaders, including Cirrus Logic, where he was the VP/GM of the Crystal Division, and IBM. He recently served as the CEO of Alereon Inc., where he led the strategy and product development of the industry’s first gigabit OFDM wireless solution.

Broockman holds numerous US patents, is an active inventor, and was a National Science Foundation Fellow. Broockman holds a BS and MS in Engineering from the University of Florida where he graduated with highest honors. Broockman is also a graduate of the prestigious UNC Chapel-Hill Executive Program in Business Administration.

About Extreme Networks:
Extreme Networks, Inc. sets the new standard for superior customer experience by delivering network-powered innovation and best-in-class service and support. The company delivers high-performance switching and routing products for data center and core-to-edge networks, wired/wireless LAN access, and unified network management and control.  Our award-winning solutions include software-defined networking (SDN), cloud and high-density Wi-Fi, BYOD and enterprise mobility, identity access management and security.  Extreme Networks is headquartered in San Jose, CA and has more than 12,000 customers in over 80 countries.

For more information, visit the company’s website at http://www.extremenetworks.com

Media Contacts:
Gregory Cross
Extreme Networks Public Relations
1 408 579 3483
gcross@extremenetworks.com

Jennifer Grabowski
Racepoint Global
1 617 624 3231
Extreme@racepointglobal.com

(NNVC) Demands Retraction of the Baseless and Inaccurate Libelous Article

NanoViricides, Inc. (NYSE MKT:NNVC) (the “Company”) has demanded from Seeking Alpha the removal of a damaging, baseless and inaccurate article posted by a person who was shorting NNVC common stock.

It is obvious that the anonymous author of this article orchestrated the publication of this article in connection with a massive short position which this person was a major beneficiary of, possibly in collusion with others. The article was clearly designed to manipulate the price of the Company’s common stock downwards for significant personal gains for the persons with short position in the stock including this anonymous author, at the expense of the Company’s shareholders. The article is pure libel, full of numerous false statements, inaccuracies, innuendos, is not based on any factual information about the Company, and twists many facts to fit the person’s motivation to cause a damaging view about the Company. The article has caused significant damage to the Company and its shareholders.

The Company has demanded retraction of the article from the SeekingAlpha website and disclosure of the identity of the anonymous person who posted it. The full text of the demand is posted on our website under the item: “NanoViricides Demands Retraction of the Damaging Article by an Anonymous Short Seller Posted on SeekingAlpha Website”.

The Company is also preparing a complaint to file with the Securities and Exchange Commission to request it to investigate this stock price manipulation.

NanoViricides, Inc. is fully prepared to seek appropriate legal action against parties involved in this libelous attack.

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company’s novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.